Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published May 27, 2021 | Supplemental Material
Journal Article Open

Optimized Photoactivatable Lipid Nanoparticles Enable Red Light Triggered Drug Release

Abstract

Encapsulation of small molecule drugs in long-circulating lipid nanoparticles (LNPs) can reduce toxic side effects and enhance accumulation at tumor sites. A fundamental problem, however, is the slow release of encapsulated drugs from these liposomal systems at the disease site resulting in limited therapeutic benefit. Methods to trigger release at specific sites are highly warranted. Here, it is demonstrated that incorporation of ultraviolet (UV-A) or red-light photoswitchable-phosphatidylcholine analogs (AzoPC and redAzoPC) in conventional LNPs generates photoactivatable LNPs (paLNPs) having comparable structural integrity, drug loading capacity, and size distribution to the parent DSPC-cholesterol liposomes. It is shown that 65–70% drug release (doxorubicin) can be induced from these systems by irradiation with pulsed light based on trans-to-cis azobenzene isomerization. In vitro it is confirmed that paLNPs are non-toxic in the dark but convey cytotoxicity upon irradiation in a human cancer cell line. In vivo studies in zebrafish embryos demonstrate prolonged blood circulation and extravasation of paLNPs comparable to clinically approved formulations, with enhanced drug release following irradiation with pulsed light. Conclusively, paLNPs closely mimic the properties of clinically approved LNPs with the added benefit of light-induced drug release making them promising candidates for clinical development.

Acknowledgement

N.C. and J.M. contributed equally to this work. The authors acknowledge Dr. Natalie Strynadka and Dr. Claire Atkinson from the UBC High Resolution Macromolecular Cryo-Electron Microscopy facility for support. Further, the authors acknowledge Dr. M. Affolter and Dr. H.G. Belting (Biozentrum, University of Basel, Switzerland) for providing zebrafish eggs, Dr. Jörg Huwyler (Pharmazentrum) for support with zebrafish injection and imaging, and Dr. Kai Schleicher (IMCF) for supporting quantitative image analysis of zebrafish studies (all University of Basel, Switzerland). J.M. thanks the NCI for a F99/K00 award (1F99CA253758-01). D.W. was supported by the Swiss National Science Foundation (#183923). This work was supported by NMIN (the NanoMedicines Innovation Network), a member of the Networks of Centres of Excellence Canada program.

Copyright and License

© 2021 Wiley-VCH GmbH

Files

smll202008198-sup-0001-suppmat.pdf
Files (257.9 kB)
Name Size Download all
md5:fbdff25068dd7d264546257be08b5181
257.9 kB Preview Download

Additional details

Created:
August 14, 2024
Modified:
August 14, 2024